Yanhong Deng
Statistician 3DownloadHi-Res Photo
Cards
Additional Titles
Senior Biostatistician
Co-Director of Analytics, Yale Center for Analytical Sciences
Contact Info
About
Titles
Statistician 3
Senior Biostatistician; Co-Director of Analytics, Yale Center for Analytical Sciences
Departments & Organizations
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yanhong Deng's published research.
Publications Timeline
A big-picture view of Yanhong Deng's research output by year.
James Dziura, MPH, PhD
David Fiellin, MD
E. Jennifer Edelman, MD, MHS, BS
Geliang Gan, MPH, PhD
Manuel Paris, PsyD
Michael Joyce
11Publications
548Citations
Publications
2025
M12 Contingency Management With Stepped Care for Unhealthy Alcohol Use Among Individuals With HIV: Initial Findings From a Multisite Randomized Controlled Trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Brown S, Ferguson T, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. M12 Contingency Management With Stepped Care for Unhealthy Alcohol Use Among Individuals With HIV: Initial Findings From a Multisite Randomized Controlled Trial. Drug And Alcohol Dependence 2025, 267: 111606. DOI: 10.1016/j.drugalcdep.2024.111606.Peer-Reviewed Original ResearchIntegrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Integrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2025, 98: 72-81. PMID: 39321757, DOI: 10.1097/qai.0000000000003534.Peer-Reviewed Original ResearchAltmetricConceptsUnhealthy alcohol useSelf-reported abstinenceAlcohol useLost to follow-upContingency managementAlcohol use disorderRandomized controlled trialsSubstance use treatmentAlcohol abstinenceFollow-upUse disorderControlled trialsPWHAlcohol treatmentAbstinenceUse treatmentEvidence of abstinenceHIVWeeksMean proportionTreatmentTrialsAlcoholDaysParticipants
2024
Psychosocial Evaluation of Living Kidney Donors: A Survey of Current Practices in the United States
Clifton E, Winder G, Lentine K, Zimbrean P, Yadav A, Rubman S, Kalil R, Kumar V, Prashar R, Gan G, Deng Y, Joyce M, Holmes R, Laflen J, Bakhai D, Liapakis A, Doshi M. Psychosocial Evaluation of Living Kidney Donors: A Survey of Current Practices in the United States. Transplantation 2024, 108: e382-e389. PMID: 38867351, DOI: 10.1097/tp.0000000000005095.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSubstance use disordersUse disorderActive anxiety disorderMental healthPosttraumatic stress disorderPsychosocial teamAnxiety disordersStress disorderActive suicidalitySelf-harmActivity depressionDisordersPsychosocial assessmentDepressionPsychosocial evaluationPost-donationUnited StatesClinical toolPsychosisLiving kidney donorsCannabisAnxietySuicideAbsolute contraindicationBest practicesIMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Wakelee H, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen Y, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava M, Bennett E, Gitlitz B, Felip E. IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2024, 42: lba8035-lba8035. DOI: 10.1200/jco.2024.42.17_suppl.lba8035.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNon-small cell lung cancerDisease-free survivalResected non-small cell lung cancerPD-L1Overall survivalPhase III studyITT populationResected stage IB-IIIA non-small cell lung cancerStage IB-IIIA non-small cell lung cancerStage II-IIIA non-small cell lung cancerFollow-upDisease-free survival improvementDisease-free survival benefitPD-L1 TCStage II-IIIACell lung cancerIntent-to-treatAdjuvant atezolizumabOS trendIII studiesOS endpointSecondary endpointsAtezoSafety profileLung cancerFeasibility of an Interprofessional Inpatient Educational Intervention for Patients With Decompensated Cirrhosis
Haque L, McDonough M, Deng Y, Ciarleglio M, Liapakis A, Jakab S. Feasibility of an Interprofessional Inpatient Educational Intervention for Patients With Decompensated Cirrhosis. Gastro Hep Advances 2024, 3: 615-617. PMID: 39165423, PMCID: PMC11330928, DOI: 10.1016/j.gastha.2024.03.011.Peer-Reviewed Original ResearchConceptsIn‐person validation of the Ichthyosis Scoring System
Echeandia‐Francis C, Sun Q, Asch S, Bayart C, Benjamin L, Cipriano S, Craiglow B, Dyer J, Levy M, Lilly E, Newell B, Liang J, Gan G, Deng Y, Paller A, Choate K. In‐person validation of the Ichthyosis Scoring System. Pediatric Dermatology 2024, 41: 247-252. PMID: 38234066, DOI: 10.1111/pde.15508.Peer-Reviewed Original ResearchAltmetricConceptsInterrater intraclass correlation coefficientsIntrarater reliabilityIn-personIntraclass correlation coefficientIn-person evaluationContent validityInterrater reliabilityHeterogeneous group of skin disordersGroup of skin disordersIntraraterMedical professionalsInterrater agreementErythema evaluationIchthyosis subtypesPhotographic evaluationErythema scoreInterraterErythemaQuantify severitySkin disordersClinical utilityIchthyosisScoring systemHeterogeneous groupCorrelation coefficient
2023
Clinical predictive value of renalase in post-ERCP pancreatitis
Muniraj T, Desir G, Gorelick F, Guo X, Ciarleglio M, Deng Y, Jamidar P, Farrell J, Aslanian H, Laine L. Clinical predictive value of renalase in post-ERCP pancreatitis. Gastrointestinal Endoscopy 2023, 99: 822-825.e1. PMID: 38103747, DOI: 10.1016/j.gie.2023.12.020.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPost-ERCP pancreatitisRenalase levelsPlasma renalase levelsProspective cohort studyPotential clinical roleAcute experimental pancreatitisLongitudinal regression modelsPEP patientsPlasma renalaseCohort studyTertiary hospitalClinical roleExperimental pancreatitisRenalaseAbstractTextERCPPancreatitisFurther studiesAIMSRegression modelsHERV1-env Induces Unfolded Protein Response Activation in Autoimmune Liver Disease: A Potential Mechanism for Regulatory T Cell Dysfunction.
Subramanian K, Paul S, Libby A, Patterson J, Arterbery A, Knight J, Castaldi C, Wang G, Avitzur Y, Martinez M, Lobritto S, Deng Y, Geliang G, Kroemer A, Fishbein T, Mason A, Dominguez-Villar M, Mariappan M, Ekong U. HERV1-env Induces Unfolded Protein Response Activation in Autoimmune Liver Disease: A Potential Mechanism for Regulatory T Cell Dysfunction. The Journal Of Immunology 2023, 210: 732-744. PMID: 36722941, PMCID: PMC10691554, DOI: 10.4049/jimmunol.2100186.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAutoimmune hepatitisDe novo autoimmune hepatitisRegulatory T cell dysfunctionUnfolded protein responseNovo autoimmune hepatitisTregs of patientsAutoimmune liver diseaseIL-17A productionRegulatory T cellsT cell dysfunctionTreg suppressive functionExpression of RORCER stressEndoplasmic reticulum stressTreg plasticityLiver diseaseCell dysfunctionProtein response activationT cellsUnfolded protein response activationSuppressive functionIncreased expressionEffector propertiesReticulum stressPotential mechanisms
2016
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. British Journal Of Cancer 2016, 114: 737-743. PMID: 27022826, PMCID: PMC4984865, DOI: 10.1038/bjc.2016.45.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinFemaleFluorouracilFollow-Up StudiesHumansIrinotecanLeucovorinLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrganoplatinum CompoundsOxaliplatinPancreatic NeoplasmsPeritoneal NeoplasmsPrognosisProspective StudiesSurvival RateConceptsProgression-free survivalAdvanced pancreatic cancerPhase II studyOverall survivalAdverse eventsPancreatic cancerII studyResponse rateMedian progression-free survivalMulticentre phase II studyFluorodeoxyglucose positron emission tomographyUse of FOLFIRINOXMedian overall survivalHistorical control patientsMetastatic pancreatic cancerFirst prospective studyPositron emission tomographyControl patientsMetastatic diseaseProspective studyProspective dataFOLFIRINOXLAPCEmission tomographyPatientsTHU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival
Bhutta A, Garcia-Tsao G, Reddy R, Tandon P, Wong F, O’Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. THU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival. Journal Of Hepatology 2016, 64: s245. DOI: 10.1016/s0168-8278(16)00253-1.Peer-Reviewed Original ResearchCitations
News
News
- May 29, 2024
Renalase May Predict Post-ERCP Pancreatitis
- January 11, 2023
Discoveries & Impact (January 2023)
- March 17, 2022
Discoveries & Impact (March 2022)
- August 11, 2021
Discoveries & Impact (August 2021)
Get In Touch
Contacts
Locations
300 George Street
Academic Office
Ste Suite 555
New Haven, CT 06511